Skip to main content
. 2014 Mar;99(3):458–464. doi: 10.3324/haematol.2013.095158

Figure 4.

Figure 4.

Event-free survival (A) and failure-free survival (B) of patients who achieved complete cytogenetic response (CCyR) without major molecular response (MMR) (n=23) (CCyR+MMR−), CCyR with MMR without complete molecular response (CMR) (n=92) (CCyR+MMR+CMR−) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on imatinib (IM) therapy. Event-free survival was measured from the date of the first CCyR on IM therapy to the date of the first event.